
ICON Public Limited Company ICLR
$ 182.75
-0.51%
Annual report 2024
added 12-06-2025
ICON Public Limited Company Accounts Payables 2011-2025 | ICLR
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables ICON Public Limited Company
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 173 M | 132 M | 81.2 M | 90.8 M | 51.1 M | 24 M | 13.3 M | 18.6 M | 8.7 M | 7.02 M | 2.79 M | 4.59 M | 8.15 M | 5.34 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 173 M | 2.79 M | 44.3 M |
Quarterly Accounts Payables ICON Public Limited Company
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 63.5 M | 90.8 M | 62.6 M | 37.8 M | 48.1 M | 51.1 M | 28.7 M | 32.7 M | 23.3 M | 24 M | 20.8 M | 20.2 M | 19.3 M | 13.3 M | 15.3 M | 15.1 M | 11.8 M | 18.6 M | 13 M | 7.86 M | 13.6 M | 8.7 M | 5.05 M | 6.12 M | 5.65 M | 7.02 M | 4.53 M | 6.3 M | 3.86 M | 2.79 M | 5.91 M | 10.9 M | 6.66 M | 4.59 M | 8.85 M | 11.8 M | 6.79 M | 8.15 M | 9.33 M | 8.07 M | 5.49 M | 5.34 M | 6.52 M | 4.29 M | 8.61 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 90.8 M | 2.79 M | 17.6 M |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
63.1 M | $ 20.97 | -1.38 % | $ 226 M | ||
|
Accelerate Diagnostics
AXDX
|
4.5 M | - | -61.36 % | $ 2.46 M | ||
|
Co-Diagnostics
CODX
|
1.48 M | $ 0.23 | -4.4 % | $ 6.75 M | ||
|
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | ||
|
Castle Biosciences
CSTL
|
6.9 M | $ 39.53 | -1.4 % | $ 1.1 B | ||
|
BioNano Genomics
BNGO
|
6.96 M | $ 1.52 | - | $ 1.93 M | ||
|
DarioHealth Corp.
DRIO
|
1.13 M | $ 10.17 | 1.29 % | $ 289 M | ||
|
DexCom
DXCM
|
276 M | $ 67.51 | 0.13 % | $ 26.1 B | ||
|
Danaher Corporation
DHR
|
1.75 B | $ 230.0 | -0.45 % | $ 168 B | ||
|
Exact Sciences Corporation
EXAS
|
89.6 M | $ 101.56 | 0.02 % | $ 18.8 B | ||
|
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | ||
|
Fulgent Genetics
FLGT
|
18.4 M | $ 26.78 | -0.85 % | $ 810 M | ||
|
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M | ||
|
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
12.9 M | $ 19.47 | -1.32 % | $ 1.05 B | ||
|
Celcuity
CELC
|
9.37 M | $ 101.9 | -0.7 % | $ 4.02 B | ||
|
Anixa Biosciences
ANIX
|
525 K | $ 3.21 | -6.25 % | $ 102 K | ||
|
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
1.16 M | - | -20.0 % | $ 1.06 M | ||
|
IQVIA Holdings
IQV
|
322 M | $ 226.52 | 0.26 % | $ 41.1 B | ||
|
Guardant Health
GH
|
38.6 M | $ 103.35 | 0.94 % | $ 12.7 B | ||
|
Aspira Women's Health
AWH
|
881 K | - | -6.19 % | $ 10.5 M | ||
|
Myriad Genetics
MYGN
|
32.3 M | $ 6.44 | -1.68 % | $ 583 M | ||
|
Illumina
ILMN
|
221 M | $ 135.12 | -0.15 % | $ 21.5 B | ||
|
Charles River Laboratories International
CRL
|
140 M | $ 203.88 | - | $ 10.5 B | ||
|
ENDRA Life Sciences
NDRA
|
270 K | $ 4.94 | -3.14 % | $ 2.65 M | ||
|
Neogen Corporation
NEOG
|
79.6 M | $ 7.12 | -0.35 % | $ 1.54 B | ||
|
National Research Corporation
NRC
|
1.3 M | $ 18.74 | 0.46 % | $ 460 M | ||
|
Quest Diagnostics Incorporated
DGX
|
287 M | $ 176.16 | 0.15 % | $ 19.6 B | ||
|
Biodesix
BDSX
|
2.19 M | $ 6.76 | -0.88 % | $ 877 M | ||
|
Laboratory Corporation of America Holdings
LH
|
876 M | $ 254.32 | 0.02 % | $ 21.3 B | ||
|
IDEXX Laboratories
IDXX
|
114 M | $ 688.22 | 0.01 % | $ 56.8 B | ||
|
Pacific Biosciences of California
PACB
|
15.1 M | $ 1.77 | -5.85 % | $ 449 M | ||
|
Lantheus Holdings
LNTH
|
34.6 M | $ 66.73 | 0.07 % | $ 4.62 B | ||
|
Mettler-Toledo International
MTD
|
216 M | $ 1 419.64 | 0.11 % | $ 30.1 B | ||
|
Agilent Technologies
A
|
446 M | $ 138.31 | 0.03 % | $ 42 B | ||
|
Biomerica
BMRA
|
295 K | $ 2.7 | 1.9 % | $ 6.2 M | ||
|
Bioventus
BVS
|
23 M | $ 7.4 | 0.27 % | $ 464 M | ||
|
NeoGenomics
NEO
|
21.6 M | $ 12.33 | 0.2 % | $ 1.56 B |